Array BioPharma Inc. (NASDAQ:ARRY) stock shows rises up of 2.12% and traded at a price of $12.77 in preceding trading session.
Pomerantz LLP reported that a class action lawsuit has been filed against Array Biopharma Inc. (NASDAQ: ARRY) and certain of its officers. The class action, filed in United States District Court, for the District of Colorado, and docketed under 17-cv-02848, is on behalf of a class consisting of investors who purchased or otherwise purchased Array securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
Array is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s lead cancer drug binimetinib (MEK162) was evaluated in multiple trials and combinations, including a Phase 3 “NEMO” study versus dacarbazine in unresectable or metastatic NRAS-mutant melanoma patients.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib new drug application (“NDA”) in use for patients with NRAS-mutant melanoma; (ii) the Company was aware that this lack of supporting clinical data would not be sufficient to receive U.S. Food and Drug Administration (“FDA”) approval of binimetinib in use for patients with NRAS-mutant melanoma; and (iii) as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times.
Its 52-week range quite noticeable, lower range was $89.82% and hit highest level of $-4.66%. The overall volume in the last trading session was 1.21 Million shares. The liquidity position of firm is on noticeable level, as its current ratio was calculated as 5.40 at the same time as its debt to equity ratio stands at 0.60.
Shares of Garmin Ltd. (NASDAQ:GRMN) at the time when day-trade ended the stock finally slightly up 0.56% to close at $59.60. A unit of Garmin Ltd. (NASDAQ:GRMN), Garmin International Inc. reported that the vívofit 4, a daily activity tracker1 with an incredible 1+ year battery life – no charging necessary – and a sunlight-readable, always-on color display. Designed for 24/7 wearability, the vívofit 4 is swim- and shower-safe and features a sleek, comfortable band. The vívofit 4 is ready to go right out of the box, and can be paired with a smartphone for additional features. Easy to set up and simple to operate, all that’s left is to put it on and go.
“An activity tracker is only as effective as how often you wear it, and this is where the vívofit 4 really shines – you can set it and forget it,” said Dan Bartel, Garmin vice president of worldwide sales. “It’s the ideal device for consumers who want something reliable that they don’t need to hassle with or take off to recharge.”
Right out of the box, the vívofit 4 starts tracking steps and encourages users to stay active with a colored move bar that fills up when a user has been stationary for too long. It also assigns daily step goals based on current activity levels which automatically adjust to the user, gradually nudging them toward a healthier, more active lifestyle.
For those consumers looking for more than just basic activity tracking, the vívofit 4 can be paired with a smartphone, adding even more functionality and options, such as tracking sleep, intensity minutes and more. Forget to start or stop a timed activity? Thanks to Move IQ, the vívofit 4 is able to detect changes in a user’s movement and automatically capture and classify activities such as walking, running, biking, swimming and using an elliptical. Users can use the vívofit 4 as their everyday watch, complete with a countdown timer, stopwatch and multiple alarms. A weather widget gives a quick, illustrated look at the day’s weather. The vívofit 4 even includes Find My Phone for those who need a little extra help keeping track of their smartphone.
The volatility tends to amount of risk or uncertainty about size of changes in a security’s value; a higher volatility denotes that a security’s value can potentially be spread out over a larger range of values. The price volatility of GRMN was 1.00% for a week and 1.46% for a month as well as price volatility’s Average True Range for 14 days was 0.89. Shares price isolated positively from its 50 days moving average with 0.25% and remote positively from 200 days moving average with 11.10%.